Explore stories from Atlantic Canada.
The Science of Beer | SaltWire #beer #science #craftbeer #soundbites #discoverycentre #foodanddrink - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Moderna's RSV shot is the first messenger RNA-based vaccine not for COVID-19 to be approved in the United States. It will be sold under the brand name mRESVIA Analysts on average forecast sales for Moderna's RSV vaccine of $340 million in 2024, growing to $830.5 million next year, according to LSEG data.
GSK's Arexvy is currently approved in the U.S. for adults aged 60 and over. British drugmaker has applied to extend the approved age group to include adults aged 50-59.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US FDA pushes decision on Moderna's RSV vaccine to end of this monthExplore stories from Atlantic Canada.
Read more »
Moderna Says FDA Delaying Decision on RSV Vaccine ApprovalUS regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to “administrative constraints” at the Food and Drug Administration, the company said.
Read more »
Moderna: FDA postpones RSV vaccine approvalModerna (MRNA) has announced a setback in the anticipated approval of its RSV vaccine. The biopharmaceutical company says that the US Food and Drug...
Read more »
Moderna’s RSV Shot Wins FDA Approval for Use in Older AdultsModerna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech a second product as it seeks to move beyond its reliance on the fading Covid-19 market.
Read more »
Moderna’s mRNA Dreams Meet Reality With First Post-Covid ShotThe biotech’s lackluster new RSV vaccine undercuts the promise of mRNA to revolutionize health care.
Read more »
Quebec to become 1st province to offer free RSV shots for infantsThis illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year.
Read more »